Moderna edges higher to $47.60 as Oxford cancer vaccine trial gains UK authorization, moderna

Traders Union
All News
Companies
Moderna rises 0.34% to $47.60 today

Highlights

MRNA trades below key short- and medium-term moving averages but remains above long-term support, reflecting continued bearish momentum.
Oscillator signals are mixed, with bearish daily momentum and buyer strength intraday, suggesting weak conviction and near-term consolidation.
Expected price range for the week is $46.00 to $50.00, with a 75% probability of moderate upward movement barring a breakdown below $46.00.

Bearish bias sustained as price holds above long-term support

MRNA is trading at $47.60, sitting below both the MA-20 ($48.76) and MA-50 ($49.77), signaling near-term and medium-term bearish pressure, but well above the MA-200 ($37.99), indicating continued long-term support. The Ichimoku Kijun sits at $51.59, creating immediate resistance above the current price. Near-term support is at MA-100 ($48.96), while key support remains at MA-200 ($37.99). Immediate resistance aligns with the Ichimoku Kijun ($51.59), with the next key level at MA-50 ($49.77).

Divergent intraday signals as bearish momentum meets overbought bias

Momentum signals on the D1 chart are predominantly bearish: MACD shows a strong sell and ADX is neutral, suggesting the recent price move lacks strong trend conviction. Oscillators paint a mixed picture; RSI and Stoch RSI both point to sell signals, but neither indicates clear overbought or oversold conditions, while CCI remains neutral. BBP is in overbought territory, hinting at buyer dominance intraday, creating a notable divergence from the prevailing bearish momentum from other indicators. MRNA is trading at $47.60, up from $47.44 at last week's close, reflecting a muted 0.34% gain. The current price is in the middle of this week’s range, with weekly volatility standing at 18.22%. This suggests consolidation after swings between $43.90 and $51.90.

Sideways trade expected as bullish weekly signals outweigh downside risk

For the upcoming week, the expected price range is seen between $46.00 and $50.00, safely within 20% of the current $47.60 and framing the action near the mid-range of the $22.32–$59.55 52-week spectrum. The probability of an upward move is moderate, around 75%, supported by the strong buy forecasts on RSI (W1), ADX (W1), and MACD (W1), making a pullback less likely. In the baseline scenario, MRNA trades sideways between $46.00 and $50.00. A bullish breakout above $50.00 could trigger momentum toward resistance, while a bearish move below $46.00 might expose a test of the MA-200 as lower support.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier, analysts noted that while Moderna faced short- and medium-term headwinds, pipeline progress and strategic initiatives supported its longer-term outlook. This article adds a new dimension by reassessing current momentum drivers, with investors advised to closely monitor upcoming catalysts that could influence the prevailing trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.